Eliyahu Sharon Kalif - Feb 13, 2023 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: EVP, Chief Financial Officer
Signature: /s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif
Stock symbol: TEVA
Transactions as of: Feb 13, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/15/2023, 06:20 AM
Previous filing: Feb 9, 2023
Next filing: Mar 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TEVA	Ordinary Shares	Options Exercise		+6.63K	+70.7%		16K	Feb 13, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Options Exercise	$0	-6.63K	-50%	$0.00	6.63K	Feb 13, 2023	Ordinary Shares	6.63K		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3	Restricted share units were granted on February 13, 2020, with 6,629 vesting on each of February 13, 2022, and February 13, 2023, and 6,630 vesting on February 13, 2024.